Innovus
Pharma Announces the Approval of its
Product
ProstaGorx in Canada for Benign Prostate
Hyperplasia ("BPH")
ProstaGorx is the
Ninth Innovus Pharma Product Approved in Canada
to Date
San Diego, CA,
June 4, 2018 --
InvestorsHub
NewsWire
--
Innovus
Pharmaceuticals, Inc.
("Innovus
Pharma"
or the "Company") (OTCQB Venture Market:
INNV), an emerging commercial-stage pharmaceutical company that
delivers safe, innovative and effective over-the-counter
medicine and consumer
care products to improve men's and
women's health and respiratory diseases, today announced the
approval by Health Canada of its product ProstaGorx
as a
Natural Health Product (NPN # 80085717) for the relief of urologic
symptoms (e.g. weak urine flow, incomplete voiding, frequent
daytime and night time urination) associated with mild to moderate
benign prostatic hyperplasia ("BPH"). Innovus
Pharma
expects to launch ProstaGorx
in the
next few months through the Company's website and its Canadian
Beyond Human marketing and sales
platform.
"We are very
delighted with the approval of ProstaGorx
for the
BPH indication in Canada," said Dr. Bassam Damaj,
the President and Chief Executive Officer of Innovus
Pharma.
"We currently expect ProstaGorx
to
perform very well in Canada and look forward to its launch in the
very near future. ProstaGorx
when
launched, will be the fourth product launched through our own sales
and marketing commercial efforts in Canada in addition to
Vesele,
Apeaz
and
Xyralid
and when
launched will then be our eighth product on the Canadian market
including Zestra,
Zestra
Glide and
Uxor (EjectDelay)
marketed by Orimed
Pharma
and UriVarx
through
our partnership with Acerus
Pharmaceuticals
Corporation. Another of the Company's products, AllerVarx,
a supplement for allergic rhinits,
has been approved by Health Canada, but has not yet
launched."
About the BPH
Market
An estimated 50% of
men have histologic evidence of BPH by age 50 and 75% by age 80; in
4050% of these men, BPH becomes clinically
significant. BPH
was one of the ten most common, and costly, diseases in men older
than 50 years of age in a recent study in the United
States. The
Canadian market is estimated to be 10% of the US market
size.
About
Innovus Pharmaceuticals, Inc.
Headquartered
in San Diego, Innovus
Pharma is
an emerging OTC consumer goods
and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective
non-prescription medicine and consumer care products to improve
men's and women's health and vitality and respiratory
diseases. Innovus
Pharma
delivers innovative and uniquely presented
and packaged health solutions through its (a) OTC medicines and
consumer and health products, which we market directly, (b)
commercial partners to primary care physicians,
urologists, gynecologists
and therapists, and (c) directly to consumers through our on-line
channels, retailers and wholesalers. The Company is dedicated to
being a leader in developing and marketing new OTC and branded
Abbreviated New Drug Application ("ANDA") products. The Company is
actively pursuing opportunities where existing prescription drugs
have recently, or are expected to, change from prescription (or Rx)
to OTC.
For
more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; and www.diabasens.com.
Innovus
Pharma's Forward-Looking Safe Harbor:
Statements under the
Private Securities Litigation Reform Act, as amended: with the
exception of the historical information contained in this release,
the matters described herein contain forward-looking statements
that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of
reasons that are outside the control of the Company, including, but
not limited to, projected revenues from the ProstaGorx
product
in Canada, estimated market for its products, and statements about
achieving its other development, growth, commercialization,
financial and staffing objectives. Readers are cautioned not to
place undue reliance on these forward-looking statements as actual
results could differ materially from the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company's most recent
filing on Form S-1, annual report on Form 10-K, subsequent
quarterly reports filed on Form 10-Q and other filings made with
the SEC. Copies of these reports are available from the SEC's
website or without charge from the Company.
###
Contact:
Randy
Berholtz
Innovus
Pharma
Investor Relations
Tel:
+1 858 249 7865
ir@innovuspharma.com